Anthropicが創薬に参入——AIは製薬大手の12年にわたる失敗率を打破できるか?
Anthropicは自社AIの訓練のため、顧みられない疾患を対象とした社内創薬プログラムを立ち上げた。ハイステークスな生物学応用分野への本格参入を示す動きだ。
anthropic will conduct preclinical research for neglected diseases, citing its nonprofit mission and the need for complex training data to improve its ai models. the announcement accompanied the launch of 'claude science', a tool where a ucsf researcher reportedly used claude to identify a year-old viral contamination in minutes. this strategy aligns with broader industry efforts, such as google's isomorphic labs, to cut drug development timelines from 12 to 8 years.